PTC Therapeutics, Inc. (PTCT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
$66.48+0.64%
Close 2026-09-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put PTCT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Total revenue reaches $1.08-$1.18 billion in 2026: FY26 revenue guidance $850M-$950M vs $1.08B-$1.18B target.
View ThesisRevenue is contracting — down about 43% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskPTC Therapeutics must continue to grow its revenue to justify its current valuation. Revenue grew 102% year over year, and the latest quarter beat expectations. The stock trades at 6.0× price-to-sales, above the peer median of 2.6×. This suggests the price reflects less growth than forecasted. A specific risk is the potential for a guidance cut, which could negatively impact estimates. Peer multiples imply a price about 22% above where it trades. Our read remains provisional.
Trailing returns as of 2026-09-14. PTCT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering PTCT (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for PTCT in the last 4 months.
Continue this research
Compare PTCT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PTCT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put PTCT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance R&D pipeline with new clinical candidates and studies
Sephience's outlook supports R&D pipeline advancement.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $66.48
The last 12 months of price, then the range of analyst 12-month targets from today’s $66.48.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Advance R&D pipeline with new clinical candidates and studies
Acquisition enhances R&D pipeline and growth potential.
Advances: Advance R&D pipeline with new clinical candidates and studies
Acquisition enhances R&D pipeline with new clinical candidates.
Advances: Increase total revenue to $1.08-$1.18 billion in 2026
Strong Sephience sales support revenue growth objectives.
Advances: Increase total revenue to $1.08-$1.18 billion in 2026
Strong Sephience sales support revenue growth objective.
Advances: Raise product revenue guidance to $750-$850 million
Earnings beat indicates strong product revenue potential.
Advances: Increase total revenue to $1.08-$1.18 billion in 2026
Sephience launch positively impacts earnings outlook.
Threatens: Raise product revenue guidance to $750-$850 million
Insider sale raises concerns about product revenue growth.